NEW YORK (360Dx) – Saladax Biomedical today announced an agreement to acquire the exclusive patent rights for antipsychotic drug tests from Janssen Pharmaceutica.
Saladax will have the patent rights to Janssen Pharmaceutica's diagnostic tests that determine drug levels in patients undergoing treatment with antipsychotic drugs. Financial and other terms of the deal were not disclosed.
Saladax currently offers its MyCare Psychiatry line of blood-based tests for the antipsychotic drugs risperidone and paliperidone. The immunoassays are CE marked and are available in Europe. With the deal announced today, MyCare Psychiatry will eventually include tests for clozapine, olanzapine, quetiapine, and total aripiprazole in major global markets, the firm said, adding that it expects to receive regulatory clearance for the additional four tests during the third quarter of 2018.
The firm said it anticipates submissions to the US Food and Drug Administration for the tests starting this month.